within Pharmacolibrary.Drugs.R_RespiratorySystem.R02A_ThroatPreparations.R02AA10_MyristylBenzalkonium;

model MyristylBenzalkonium
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.05,
    Cl = 2.777777777777778e-06,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.03,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0033333333333333335,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>MyristylBenzalkonium</td></tr><tr><td>ATC code:</td><td>R02AA10</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>30</td><td>L</td></tr>
    <tr><td>clearance:</td><td>10</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Myristyl-benzalkonium is a quaternary ammonium compound with antiseptic and disinfectant properties. It belongs to the same class as benzalkonium chloride and is primarily used for its antimicrobial properties, particularly in lozenges and topical formulations for the treatment of sore throat and oral cavity infections. It is not widely used today as a primary therapeutic agent, with limited approval status in most countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data available in humans or animals. Estimated parameters for typical adult oral use case.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R02AA10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end MyristylBenzalkonium;
